This is a preview of subscription content, log in via an institution to check access.
Literatur
nach Informationen der Novartis Pharma GmbH
Author information
Consortia
Rights and permissions
About this article
Cite this article
Springer Medizin-Verlag. Ruxolitinib empfohlen. best practice onkologie 9, 32 (2014). https://doi.org/10.1007/s11654-014-0563-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11654-014-0563-5